Earnings ·
Precigen reports Q3 net income of $35.8M on PAPZIMEOS revenue growth to $72.9M
PGENPrecigen, Inc.
Precigen reported third-quarter 2026 net income of $35.8 million, or $0.08 per diluted share, driven by a 37% quarter-over-quarter increase in PAPZIMEOS net product revenue to $72.9 million. The company achieved positive cash flow from operating activities of $11.9 million, reaching this milestone a full quarter ahead of its previous guidance. Total revenues for the period were $74.1 million, compared to $2.9 million in the prior-year period when no commercial sales were recorded. Additionally, Precigen received FDA Platform Technology Designation for its AdenoVerse platform and presented new long-term follow-up data demonstrating durable complete responses after PAPZIMEOS treatment for up to five years. Precigen is a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines.